Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Brief summary (registry, in English)

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 3578
• From 19 Dec 2025 to the primary completion date, 21 Sept 2027
• 185 sites in 11 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (185)

Sites in registry order. Pick your city on the disease page to sort them by distance.